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doi:10.1016/j.ejvs.2010.05.001Abstract Background: Determinants of extracellular matrix (ECM) destruction/reconstruc-
tion balance influencing abdominal aortic aneurysm (AAA) diameter may impact length.
Objective: Document aortic lengthening, its correlation to diameter, and determine how
treatments that impact diameter also affect length.
Methods: Three hundred and fifty-five diameter and length measurements were performed in
308 rats during AAA formation, expansion and stabilisation in guinea pig aortas xenografted in
rats. Impact of modulation of ECM destructive/reconstructive balance by endovascular
Vascular Smooth Muscle Cell (VSMCs) seeding, TIMP-1, PAI-1 and TGF-beta1 overexpression
on length has been assessed.
Results: Length increased in correlation with diameter during formation (correlation coef-
ficient (cc): 0.584, P< 0.0001) and expansion (cc: 0.352, PZ 0.0055) of AAAs. Overexpres-
sion of TIMP-1 and PAI-1 decreased lengthening (PZ 0.02 and 0.014, respectively)
demonstrating that elongation is driven by matrix metalloproteinases and their activation
by the plasmin pathway. Overexpression of TGF-beta1 controlled length in formed AAAs
(17.3  9.6 vs. 5.9  7.4 mm, PZ 0.022), but not VSMC seeding, although both therapies
efficiently prevented further diameter increase. Length and diameter correlation was lost
after biotherapies.Recherches Chirurgicales Dominique Chopin, CNRS EAC 7054, UFR de Me´decine, 8 Rue du Ge´ne´ral
net.fr (E. Allaire).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Aortic Length Changes During AAA Formation, Expansion and Stabilisation 469Conclusion: Length increases in correlation with diameter during AAA formation and expan-
sion, as a consequence of ECM injury driven by MMPs activated by the plasmin pathway.
Correlation between length and diameter increases is not universally preserved.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The definition of arterial aneurysms is based on diameter,
but aneurysmal aortas are also increased in length.
Although the clinical importance of aneurysmal lengthening
is increasingly recognised,1,2 its relation to diameter and its
determinants are poorly characterised.
In vitro, Dobrin et al. has demonstrated the respective
roles of elastase and collagenase activities in arterial
elongation, dilatation and rupture.3 The mechanical
behaviour of human aneurysmal wall is altered both longi-
tudinally and circumferentially,4 more severely in ruptured
abdominal aortic aneurysms (AAAs).5 These data provide
support to the concept that aortic elongation is determined
by extracellular matrix (ECM) injury.
The xenograft model of AAA has been used to unravel the
role of proteases in aneurysm formation and rupture,6,7 and
to validate concepts of endovascular cell8 and gene therapy9
in already formed, expanding lesions. Humanatherosclerotic
AAAs and the xenograft model share common determinants
of aortic ECM injury, for example, inflammation (T and B
lymphocytes, macrophages),10,11 possibly triggered by
immunity/auto-immunity,12 and involvement of matrix
metalloproteases (MMP-2, -3 and -9) activatedby the plasmin
pathway.6,7,13e15 Because the segment of xenogeneic aortic
ECM undergoing aneurysmal degeneration is topographically
delimited by two end-to-end suture lines, we thought to use
the xenograft model in rats to better characterise length
changes during AAA formation and expansion, and their
correlations to diameter. Our hypothesis was that determi-
nants of ECM destructive/reconstructive balance influencing
AAA diameter would impact length.
Material and Methods
Data sources
Length and diameter of experimental aneurysms have been
recorded in studies using the aortic xenograft model of AAA
in rats. Published data regarding diameter are summarised
in Table 1.6e9,16 Data regarding length have not been pub-
lished previously.
Xenograft implantation
Animal care complied with the European Union and United
State of America regulations. Sub-renal aortas from male
guinea pigs decellularised with sodium dodecyl sulphate,15
and grafted as 10-mm-long segments after removal of 9-mm
segments of native rat aorta (Lewis or Fischer 344) using
two end-to-end anastomoses.
Preventive treatments
Three different cell seeding approaches aimed at pre-
venting aneurysmal degeneration by blocking ECM injurywere applied endovascularly through a catheter in the
lumen, at the time of xenograft implantation, for
example, in a non-aneurysmal vessel: (1) non-genetically
engineered syngeneic vascular smooth muscle cell
(VSMCs),16 (2) VSMCs transfected with a retrovirus
encoding tissue inhibitor of matrix metalloprotease-1
(TIMP-1), a natural inhibitor of MMPs,6 (3) VSMCs trans-
fected with a retrovirus encoding plasminogen activator
inhibitor-1 (PAI-1), a natural inhibitor of tissue plasmin-
ogen activator (tPA) and urokinase-type plasminogen
activator (uPA).7 Controls were xenografts receiving
VSMCs transfected with a retroviral vector with no gene of
interest, for TIMP-1 and PAI-1 experiments, or culture
medium without cell for experiments with non-genetically
engineered VSMCs (summarised in Table 1).
Curative treatments applied to already formed
AAAs
Percentage changes are calculated in reference to the
length or diameter value for each vessel at the entry in the
observation interval, that is, at implantation for AAA
formation and at day 14 for AAA expansion. Implanted
xenografts complying with AAA definition on diameter
criteria 2 weeks after implantation were included in
treatment protocols aimed at controlling AAA diameter
expansion by modulating ECM destructive/reconstructive
balance (summarised in Table 1). Syngeneic, non-geneti-
cally engineered VSMCs,8 or a suspension of adenoviruses
encoding simian, mutated active transforming growth
factor-beta1 (TGF-beta1)9 have been delivered endovasc-
ularly. Controls were culture medium or a suspension of an
adenovirus with no gene of interest, respectively. AAAs
were measured at time of treatment, and a second time at
various delays thereafter.
Measurement method
Graft length and diameter were measured with a grid in the
eyepiece of an operative microscope under beating heart,
before vessel treatment or harvest. Length was defined as
the distance between the two suture lines of the xeno-
graft. Grafts/aneurysms remained linear, for example,
with no tortuosity, even after very significant diameter
expansion. The rat aorta at vicinity of suture lines was
never dilated. Diameter was measured at the level of
maximum dilatation. Length changes were expressed as
percentages and calculated as follows: for AAA formation
experiments: (length at evaluation e length at
implantation) 100/length at treatment; for AAA expan-
sion experiments: (length at evaluation e length at day 14
endovascular injection) 100/length at endovascular
injection. Similar formulas were used to calculate diameter
percent changes.
Table 1 Summary of treatment studies.
Injected material Control Main outcome on
diameter criteria
Preventive treatments
VSMC seeding Isogenic VSMCs Culture medium Prevention of AAA
degeneration
PAI-1 overexpression PAI-1 overexpressing
isogenic VSMCs
VSMCs transfected
with no gene of interest
Prevention of AAA
degeneration
TIMP-1 overexpression TIMP-1 overexpressing
isogenic VSMCs
VSMCs transfected with
no gene of interest
Prevention of AAA
degeneration
Curative treatments
VSMC seeding Isogenic VSMCs Culture medium Suspension of AAA
diameter expansion
TGF-beta1
overexpression
Adenovirus with cDNA
encoding activated TGF-beta1
Adenovirus with cDNA
encoding beta galactosidase
Suspension of AAA
diameter expansion
470 S. Michineau et al.Statistical analysis
Data were recorded for each xenograft/AAA, in treated and
control groups when appropriate, and were expressed as
means standard deviation. Using StatView 5.0 for PC,
treated and control groups for evaluation of treatment
were compared with the non-parametric ManneWhitney U-
test (less than 10 AAA per group). An paired t-test was used
to compare percent changes of length or diameter of
a same xenograft/AAA between two time points during AAA
formation or expansion, or in response to treatment. An
analysis of variance (ANOVA) followed by a protected least
significant difference (PLSD) Fischer test was used for
comparisons between more than two time points during
AAA formation and expansion. A correlation coefficient
between diameter and length for each graft was calcu-
lated. P< 0.05 was accepted as significant.
Results
There was no difference between Lewis and Fischer 344 rat
strains, nor between operators (EA or JD), regarding length
and diameter at engraftment and at 14 days (not shown).
Shapes of formed AAAs in the model varied widely, from
fusiform, to ‘sausage like’ and saccular, pretty much as in
human atherosclerotic AAAs.A
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Figure 1 Length and diameter during expansion of experimenta
expansion. (B) Correlation between relative length and diameter cLength during AAA formation and expansion
Percentage changes are calculated in reference to the
length or diameter value for each vessel at the entry in the
observation interval, for example, at implantation for AAA
formation and at day 14 for AAA expansion.
During AAA formation, percentages of length changes
were 14.7 15.1% at 1 week (nZ 11) and 36.8 27.8% at 2
weeks (nZ 164), respectively, in reference to value at
implantation (PZ 0.013). Diameter changes were
43.4 26.5% at 1 week (nZ 11) and 107.2 43.5% at 2
weeks (nZ 164) (PZ 0.01). Diameter and length increase
were correlated (correlation coefficient (CC): 0.584, 95%,
confidence interval (CI): 0.493e0.662 P< 0.0001).
During AAA expansion, length continued to increase:
11.6 12.3% at 1 week (nZ 14), 11.9 15.3% at 4 weeks
(nZ 38) and 11.9 15.3% at 8 (nZ 18) weeks (Fig. 1(A)).
Diameter also increased: 21.3 13.1% at 1 week (nZ 14),
34.5 46.3% at 4 weeks (nZ 38) and 92.2 143.3,
34.1 18.0% at 8 (nZ 18) weeks (Fig. 1(A)).
Length-to-diameter ratio, calculated from the values of
lengths and diameters expressed in mm, were 3.7 0.8 at 1
week and 3.4 1.1 at 8 weeks (PZ 0.59).
The correlation between diameter and length percent
changes during AAA expansion was strong (analysis pooling
vessels at the three delays) (CC: 0.832, 95% CI:02-
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l AAAs. (A) Relative length and diameter changes during AAA
hanges during expansion. **P< 0.01. NS: non-significant.
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analysis has been performed after exclusion of 10 AAAs with
extreme length and diameter changes, for example, over
40% and 100%, respectively. After exclusion of these
outliers, the correlation was maintained (CC: 0.352, 95% CI:
0.108e0.556; PZ 0.0055) (Fig. 1(B)).
Length in treatment studies
Comparisons between treated and non-treated
vessels
Data comparing untreated vessels and vessels after
preventive or curative treatments at latest observation
time point are summarised in Table 2.
Analyses of length over time within treated vessel
groups
Length evolution in preventive treatments (applied
before AAA degeneration)
The experimental design of studies is presented in Fig. 2(A).
Length of non-aneurysmal vessels seeded by VSMCs was
stable over time (percent of length changes at: 1 week:
1.2 2.4% (nZ 4); 2 weeks: 3.2 3.8% (nZ 6); 8
weeks: 4.4 16.2% (nZ 8) (NS); conversely, the diameter
of the same vessels had increased at 1 week (45.3 19.4%,
nZ 4). It remained unchanged at 2 (46.8 8.6%, nZ 6) and
8 weeks (42.0 16.6%, nZ 8) after treatment (NS)). As
a consequence of discrepancies between length and diam-
eter, correlation was lost (CC: 0.381, 95% CI:
0.104e0.720; PZ 0.12) (Fig. 2(B)).
To test the impact of ECM degradation on AAA forma-
tion, TIMP-1 and PAI-1 were overexpressed in Fischer 344
rat VSMCs with a retroviral vector. Compared with their
respective controls, both TIMP-1 and PAI-1 overexpression
were followed by length stability over 4 weeks (Table 2).Table 2 Impact of treatments on length and diameter, in comp
Diameter (% of change)
Control Treated
Preventive treatments
VSMC seedinga 275.2 279.7
(nZ 6)
42.0 16.7
(nZ 8)
PAI-1 overexpressionb 395.8 137.1
(nZ 6)
60.1 15.4
(nZ 6)
TIMP-1 overexpressionb 395.8 137.1
(nZ 6)
43.0 8.3
(nZ 6)
Curative treatments
VSMC seedinga 261.3 236.9
(nZ 5)
10.6 9.4
(nZ 12)
TGF-beta1 overexpressionb 66.0 37.9
(nZ 8)
11.9 20.6
(nZ 10)
a At eight weeks.
b At four weeks.
c ManneWhitney U-test.Length evolution in curative treatments (applied to
already formed AAAs)
In these experiments, length and diameter percent changes
were calculated in reference to values in AAAs at time of
treatment injection (day 14 after xenograft implantation)
(see experimental design in Fig. 3(A)).
(1) VSMCs seeding in already formed AAAs. Length of AAAs
seeded by VSMCs was stable over time (6.0 7.0% at 1
week (nZ 15) and 4.5 4.7% at 8 weeks (nZ 12) (NS)).
Diameter was also stabilised (3.0 17.1% at 1 week
(nZ 15) and 5.2 8.0% at 8 weeks (nZ 12) (NS)).
However, there was no correlation between diameter
and length percent changes after VSMCs seeding: CC:
0.019, 95% CI: 0.396e0.363; PZ 0.93) (Fig. 3(B)).
(2) TGF-beta 1 overexpression in already formed AAAs.
Length of AAAs was stable over time after TGF-beta1
overexpression (2.5 4.1% at 2 (nZ 10) and 5.9 7.4%
at 4 weeks (nZ 10) (PZ 0.496)). Diameter was also
stabilised (1.8 4.1% at 2 (nZ 10), and 11.9 20.6% at
4 weeks (nZ 10) (PZ 0.321)). As for cell therapy, gene
therapy failed to maintain a correlation between length
and diameter changes, after excluding an outlier AAA
with a major diameter increase: CC: 0.150, 95% CI:
0.119e0.223, PZ 0.223).
Discussion
Measuring length of AAA in humans is difficult, technically
and conceptually.17,18 Moreover, AAA length may expand
not only by elongation of the initial aneurysmal segment,
but also by disease extension at the expense of necks.19 In
the xenograft model, it is possible to quantify the conse-
quences of proteolysis-driven destruction of a defined
segment of aortic ECM on aortic elongation. We demon-
strate that length increases in correlation with diameter
during AAA formation and expansion, as a consequence of
ECM injury driven by MMPs activated by the plasminarison with control groups.
Length (% of change)
P c Control Treated P c
0.0002 38.9 51.0
(nZ 6)
4.4 16.2
(nZ 8)
0.011
0.014 56.5 18.2
(nZ 6)
7.3 10.2
(nZ 6)
0.014
0.02 56.5 18.2
(nZ 6)
0.12 4.1
(nZ 6)
0.02
0.014 58.5 76.2
(nZ 5)
8.9 0.3
(nZ 12)
NS
0.0015 17.3 9.6
(nZ 8)
5.9 7.4
(nZ 10)
0.022
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Figure 2 Length and diameter after preventive treatments of AAA formation. (A) Experimental design of preventive studies.
(B) Impact of endovascular seeding of VSMCs with no genetic manipulation on correlation between relative length and diameter
changes of already formed AAAs.
472 S. Michineau et al.pathway. We also show that correlation between length and
diameter increases is not universally preserved.
The magnitudes of length increase (14.7% and 36.8%)
during experimental AAA formation compares to the 27%
length increase of the sub-renal aorta in human AAAs inyparehtCMSV
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Figure 3 Length and diameter of already formed AAAs treated by
studies. (B) Impact of endovascular VSMCs therapy on correlation
TGF-beta1 gene therapy on correlation between relative length anreference to non-aneurysmal aortas.20 The mean length-to-
diameter ratio of human AAAs is fairly constant
(1.39e1.67),21 as in our study, although ratios in the
experimental model, calculated from values in millimetres,
are different (3.4e3.5). The formation of the AAA was%
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between relative length and diameter changes. (C) Impact of
d diameter changes of already formed AAAs.
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guinea pig aorta. Sub-renal rat and guinea pig aortic
diameters were similar (data not shown).
We demonstrate in vivo that aortic elongation during
AAA formation is the consequence of a MMP-driven
proteolysis, since it can be inhibited by TIMP-1 over-
expression. We also show that activation of MMPs by
enzymes of the plasmin pathway is instrumental, since the
blocking of tPA and uPA by PAI-1 overexpression prevents
aortic elongation. Our results demonstrate the role of ECM
integrity in maintaining aortic length in vivo, and the
destabilising role of MMPs activated by the plasmin
pathway.
We provide the first demonstration that aortic ECM
degradation by inflammation and proteolysis has a conver-
gent impact on length and diameter changes. However, our
data also show that, depending on local factors used to
modulate the ECM destruction/reconstruction balance, the
correlation between diameter and length increases is not
always maintained. This finding is concordant with the
clinical observation that patients may have particularly
tortuous aorto-iliac vessels, independently of the diameter
of their aneurysms. We have identified two mechanisms
whereby correlation is lost. One is heterogeneous evolution
of vessels with regard to length and diameter within one
group of treatment, for example, VSMC seeding into
already formed AAAs. Some vessels within one group
clearly expand in length, not in diameter, and vice versa.
This is also the case after endovascular gene therapy,
although in a lesser extent. The other mechanism is
divergent evolution of diameter and length for all vessels
within one treatment group, for example, preventive
seeding at 1 week. Collectively, these data suggest that
under some circumstances, AAA remodelling does not
happen simultaneously in all three directions in space. One
reason may be that the endovascular seeding results into
an uneven accumulation of VSMCs along the vessel, with
ensuing local heterogeneities in ECM destructive/recon-
structive balance. We have observed that after 48 h,
accumulation of seeded cells sticking to the lumen of the
aortic ECM is heterogeneous, with clusters of cells in
discrete areas (E. Allaire, unpublished result). In addition
to our data, it has been reported that the repartition of
MMP activity along human AAAs is heterogeneous.22 The
maximum diameter of an AAA is the consequence of a very
focal destruction of ECM along the aorta. Conversely,
lengthening results from the addition of multiple focal
degradations of ECM on the longitudinal axis.Study limitations
Our study has limitations. The xenograft model does not
reproduce aorto-iliac tortuosity, wall calcifications and
extension of atherosclerotic disease to other arterial
segments. All these characteristics of the human disease
may have an impact on aortic remodelling, and, therefore,
may have an additional impact on the relationship between
length and diameter increase. In addition, shapes of formed
AAAs were not recorded in this study. The lack of
accounting for this variable may have induced more vari-
ability in the regression results.Clinical relevance
Angulation modulates the risk of rupture of AAAs.1,2 Feasi-
bility and complexity of endovascular aneurysm repair
(EVAR) are modulated by aortic and iliac angulation, pres-
ence of hostile necks characterised by shortness and severe
angulation, all related to elongation.23,24 Short necks are risk
factors for limited durability of EVAR because of per-proce-
dure and long-term type I endoleaks,25 and increase rates of
re-operation26 and aneurysm-related death.27
Length changes contribute toEVARdurability. Longitudinal
shrinkage causes stent-graft kinking and limb failure.28,29
Post-EVAR neck shortening is associated to neck diameter
increase, another illustration of the tri-dimensional aspect of
aortic enlargement, and causes type I endoleak,30 a major
mechanism leading to secondary AAA rupture.27 Whether
entire coverage from neck to end of common iliac by stent
graft may help controlling proteolysis and length changes is
another important issue for EVAR durability.
In contrast to EVAR, results of open surgery may not be
affected by aorto-iliac length and tortuosity. A better
appreciation of aorto-iliac lengthening may help to stratify
risks and benefits, and, for identified patients, may shift
the balance towards one technique or the other. This is
particularly relevant since mortality related to re-operation
after EVAR failure likely contributes to the decline of the
benefit of EVAR over surgery.31,32
Conclusion
When a segment of aortic ECM is exposed to a proteolytic
injury together with longitudinal and radial strains in vivo,
length increases in correlation to diameter. Length expan-
sion is driven by MMPs activated by the plasmin pathway,
and can be suspended by selective inhibition by TIMP-1 or
PAI-1. Under some circumstances, heterogeneity of aortic
wall remodelling may occur along the AAA and disrupt
correlation between length and diameter evolution.
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